As has been previously demonstrated in the context of MM, it has been shown that various pharmacologic agents can be combined with αCD38 antibody to augment its efficacy by increasing CD38 expression on target tumor cells [6, 8, 9]. The gene discussed is CD38; the disease is Miyoshi myopathy.